(R) Cantargia: abstract published for the oral presentation of antibody CAN04 phase I data at ASCO

Cantargia AB today announces that the abstract of the upcoming oral presentation of CAN04 phase I clinical data at the 2019 ASCO Annual Meeting is published on the confer...

(R) Cantargia announces new pre-clinical results showing consistent positive effects of the antibody CAN04 when combined with platinum-based chemotherapies

Cantargia AB today announces new pre-clinical results from the antibody CAN04 (nidanilimab) in combination with platinum-based chemotherapies. Cantargia has previously re...

(R) Cantargia signs agreement with Patheon Biologics B.V. for production of antibody CAN04

Cantargia AB (publ) and Patheon Biologics B.V. (part of ThermoFischer Scientific) have signed an agreement regarding future production of the antibody CAN04 (nidanilimab)...

(R) New number of shares and votes in Cantargia

(R) Notice of Annual General Meeting in Cantargia AB (publ)

The shareholders of Cantargia AB (publ) are invited to the Annual General Meeting on Monday, 27 May 2019, at 4 p.m. CET at Medicon Village, Scheelevägen 2, Lund, Sweden.

(R) Cantargia phase I clinical results on the antibody CAN04 selected for oral presentation at ASCO

Cantargia AB today announce that the phase I clinical data generated by the antibody CAN04 will be presented orally at the 2019 Annual ASCO meeting May 31 – June 3, 2019 ...